Vyome Holdings Inc (HIND) Stock Price, Quote & News

Company Profile

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: 973-832-8147

Website: www.vyometx.com

Address:

Harvard Square, One Mifflin Place Suite 400, Cambridge, United States

OlindoFL Dec. 24 at 3:40 PM

$HIND LOL that there are still Sunshine Pumpers for this steaming turd! 💩

0 · Reply

DARKP00L Dec. 22 at 1:10 PM

$HIND 08:06 on Dec. 22 2025 Vyome Holdings Subsidiary, LiveChain, To Acquire Senior Secured Note In Humanyze; LiveChain To Issue Shares Of ~$325K In Exchanve #tradeideas

0 · Reply

Stock_Catcher Dec. 22 at 1:00 PM

$HIND Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

0 · Reply

HumanityFirst Dec. 17 at 2:29 AM

$HIND anyone who was involved in this scam against retail investors - see you in court.

1 · Reply

HumanityFirst Dec. 10 at 4:33 AM

$HIND The asset sale was a major fraud against investors.

1 · Reply

Shane393 Dec. 9 at 7:36 PM

$HIND what a fukin scam Reshape 2.0

0 · Reply

Fl1p_M0p_GaZ Dec. 9 at 3:18 PM

$HIND When I see Next NRG holding this $7M+ monthly zone and stacking triple-digit YoY rates while Q3 already hit $22.9M up 232% YoY, I think the long-term multiple expansion story becomes more plausible with each new update 🚀

0 · Reply

tWiStY_JaMbOx Dec. 9 at 3:18 PM

$HIND I’m stacking the Next NRG receipts not just the headline $7.51M November +271% YoY vs $2.02M on top of $7.39M October +196% vs $2.50M is the kind of 2-month combo that builds real long-term trust 🚀

0 · Reply

Shane393 Dec. 8 at 10:48 PM

$HIND Vyome says "Huge step forward" these guys are desperate trading at 1/3 of what reshape was worth. Month pivots show this is going down more it simply popped a few cents above previous month value to take more victims here so short away.

0 · Reply

VyomeInc1 Dec. 8 at 7:14 PM

$HIND Huge step forward! Vyome reports positive final Phase 2 results for VT1953 for treating symptoms of malignant fungating wounds — a condition with no FDA-approved treatments today. ✔️ bad smell reduction - Primary endpoint met (strong significance) ✔️ Symptom improvements that matter to patients ✔️ Potential path toward Orphan Drug Designation ✔️ FDA interactions + pivotal study start in 2026 Clean structure. Strong team. Real progress. More ahead. #Biotech #ClinicalTrials #Inflammation

3 · Reply

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Dec 8, 2025, 8:00 AM EST - 16 days ago

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Nov 25, 2025, 7:00 AM EST - 4 weeks ago

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Nov 18, 2025, 7:00 AM EST - 5 weeks ago

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Nov 5, 2025, 10:13 AM EST - 7 weeks ago

Market Cap	20.49M
Revenue (ttm)	8.01M
Net Income (ttm)	-7.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.01%
Debt to Equity Ratio	0.00

Volume	5,700
Avg Vol	51,322
Day's Range	N/A - N/A
Shares Out	5.64M
Stochastic %K	15%
Beta	1.21
Analysts	Strong Sell
Price Target	$15.00